Loading company…
OSENSUS develops AI tools and treatment solutions for precision oncology.
OSENSUS develops AI-driven precision oncology diagnosis and treatment solutions, including AIMPO, using proteomics, multi-omics and a small-sample AI architecture. It works with hospitals on clinical trials and advances medical device registration, trials and drug CRO services. Founded in 2025 in Hangzhou, China, it raised Seed funding from Goldport Capital in June 2026.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in